Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% returns, respectively, over the same period. The fund underperformed while the S&P 500 and Nasdaq-100 posted their best quarter in six years. A significant factor in this decline is a ~30% concentration in Alphabet stock, which shifted from a cash-generating asset to a capital-intensive posture following a major stock offering to fund data centers. The performance of the fund was further hampered by losses in AI semiconductor stocks like AMD and Intel, which were sold prematurely. The letter concluded with a commitment to risk management while acknowledging the possibility of mistakes in investment strategy. In addition, please check the fund’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Insiders Fund highlighted Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is a global healthcare company that develops and manufactures medical devices, diagnostics, and nutritional products. On August 13, 2026, Abbott Laboratories (NYSE:ABT) closed at $111.27 per share, with a market capitalization of $192.54 billion. Abbott Laboratories (NYSE:ABT) posted a one-month return of 10.52%, while its shares lost 15.54% over the past 52 weeks.
Insiders Fund stated the following regarding Abbott Laboratories (NYSE:ABT) in its Q2 2026 investor letter:
“Business: Abbott Laboratories (NYSE:ABT) is a global healthcare leader focused on life-changing technologies. Founded in 1888, the company operates across four primary segments: Diagnostics, Medical Devices, Established Pharmaceuticals, and Nutrition. Abbott is widely recognized for its “Dividend King” status, having increased its dividend for over 50 consecutive years. Key products include the FreeStyle Libre glucose monitoring system and the BinaxNOW rapid tests.
Insider Buying/Selling: Insider Buying/Selling: Insiders are significant buyers. John G. Stratton (Director): Purchased 2,000 shares on May 7, 2026, at an average price of $86.82 per share (totaling $173,640). Daniel J. Starks (Director): Purchased 10,000 shares on April 27, 2026, at an average price of $92.65 per share (totaling $926,537). Earlier in the year on February 4, 2026, he also purchased a total of 10,000 shares split across two transactions at prices of $108.33 and $109.14.…” (Click here to read the full text)
Abbott Laboratories (NYSE:ABT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 73 hedge fund portfolios held Abbott Laboratories (NYSE:ABT) at the end of the fourth quarter, compared to 71 in the previous quarter. While we acknowledge the risk and potential of Abbott Laboratories (NYSE:ABT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Abbott Laboratories (NYSE:ABT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered whether Abbott Laboratories (NYSE:ABT) offers a stronger long-term opportunity. Matrix Asset Advisors added Abbott Laboratories (NYSE:ABT) to its portfolio during Q2 2026 given its recurring revenue, robust balance sheet, consistent dividend growth and attractive valuation. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
